Monaco Asset Management SAM Sells 50,000 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Monaco Asset Management SAM lowered its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 50.0% during the 3rd quarter, Holdings Channel.com reports. The firm owned 50,000 shares of the company’s stock after selling 50,000 shares during the quarter. Monaco Asset Management SAM’s holdings in Teva Pharmaceutical Industries were worth $1,010,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. Phoenix Financial Ltd. grew its holdings in Teva Pharmaceutical Industries by 9.4% during the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock worth $834,164,000 after buying an additional 3,533,800 shares in the last quarter. National Pension Service lifted its stake in Teva Pharmaceutical Industries by 24.2% during the 3rd quarter. National Pension Service now owns 2,073,293 shares of the company’s stock valued at $41,881,000 after acquiring an additional 404,526 shares in the last quarter. Oak Harvest Investment Services purchased a new position in Teva Pharmaceutical Industries during the 3rd quarter worth $1,010,000. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 12.9% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock worth $761,455,000 after acquiring an additional 4,306,363 shares in the last quarter. Finally, Public Sector Pension Investment Board grew its stake in shares of Teva Pharmaceutical Industries by 11.5% in the 3rd quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock worth $13,543,000 after acquiring an additional 69,000 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 77,400 shares of the firm’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total value of $2,340,576.00. Following the completion of the transaction, the director directly owned 367,600 shares of the company’s stock, valued at $11,116,224. This trade represents a 17.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Amir Weiss sold 12,300 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total value of $371,460.00. Following the completion of the transaction, the chief accounting officer owned 5,650 shares of the company’s stock, valued at approximately $170,630. This trade represents a 68.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 422,060 shares of company stock valued at $12,254,965 in the last quarter. Corporate insiders own 0.49% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on TEVA. Scotiabank boosted their price target on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a report on Thursday, January 29th. Bank of America increased their price target on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Jefferies Financial Group upped their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. The Goldman Sachs Group boosted their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Finally, Truist Financial increased their price target on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.56.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $34.24 on Friday. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $37.35. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80. The stock’s fifty day moving average price is $32.57 and its two-hundred day moving average price is $25.07. The firm has a market cap of $39.37 billion, a PE ratio of 28.53, a PEG ratio of 11.49 and a beta of 0.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.31. The company had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.